Rare oncology diseases present inherent challenges for interventional clinical trials. To enhance the quality of clinical discovery, participant experience, and overall chances for success, there is a steady increase in the role of specialized research consortia. These groups of experts, including medical doctors and scientists, ensure more targeted and effective research by working with clinical site networks and addressing the challenges specific to the rare oncology space. The focus is shifting from a trial-centric to a patient-centric approach, which enhances trial rigor and gives patients a scientific voice in tandem with patient advocacy groups (PAGs).
Read our guide to explore more about:
- How consortia are currently shaping clinical trial design in rare oncology
- How to create effective engagement with consortia and the associated added value to your clinical trial
- The interrelationship between a sponsor, CRO, consortium, and PAGs for protocol design
